LakeShore Biopharma Calls Special Meeting to Vote on Going-Private Merger
LakeShore Biopharma will hold an extraordinary general meeting on June 19, 2026, to approve a merger that would take the company private, delisting its shares from the OTC Markets.
LakeShore Biopharma Co., Ltd, a global biopharmaceutical company focused on vaccines and therapeutic biologics, has called an extraordinary general meeting of shareholders to vote on a merger agreement that would take the company private. The EGM is scheduled for June 19, 2026, at 1:00 p.m. Beijing time in Beijing, China.
Under the terms of the merger agreement, originally signed on November 4, 2025, and amended on April 29, 2026, LakeShore Biopharma would merge with a subsidiary of Oceanpine Skyline Inc., becoming a wholly owned subsidiary of Parent. Upon completion, the company's ordinary shares and warrants would no longer be listed on any public market, including the OTC Pink tier of the OTC Markets, and would cease to be registered under the Securities Exchange Act of 1934.
Shareholders of record as of May 27, 2026, are entitled to vote at the EGM. The company's board of directors, following the unanimous recommendation of a special committee of independent directors, has approved the merger and recommends shareholders vote in favor. The proposal includes authorizing the merger agreement, the plan of merger, and related transactions.
The move to go private comes as LakeShore Biopharma, formerly known as YS Biopharma, continues to develop its proprietary PIKA® immunomodulating technology platform and vaccines for rabies, hepatitis B, influenza, and other infectious diseases. The company operates in China, Singapore, and the Philippines, and its management team combines local and global biopharmaceutical expertise.
Additional details about the EGM and the merger are available in the transaction statement on Schedule 13E-3 and the definitive proxy statement filed with the U.S. Securities and Exchange Commission. These documents can be accessed on the SEC's website at http://www.sec.gov. Shareholders are urged to read these materials carefully, as they contain important information about the proposed merger.
The company cautions that forward-looking statements in the announcement involve risks and uncertainties, including how shareholders will vote, potential termination of the merger agreement, competing offers, and financing availability. Other risks are detailed in the company's SEC filings.
For investor inquiries, LakeShore Biopharma can be reached by phone at +86 (10) 8920-2086 or by email at ir@lakeshorebio.com. More information about the company is available at https://investors.lakeshorebio.com/.
The outcome of the EGM will determine whether LakeShore Biopharma transitions from a publicly traded entity to a privately held company, a significant strategic shift that could impact its future operations and access to capital markets. Shareholders are advised to vote by the deadline.